These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18067103)

  • 1. Patient empowerment in the management of hyperphosphatemia.
    Kuhlmann MK; Hoechst S; Landthaler I
    Int J Artif Organs; 2007 Nov; 30(11):1008-13. PubMed ID: 18067103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease.
    Ahlenstiel T; Pape L; Ehrich JH; Kuhlmann MK
    Nephrol Dial Transplant; 2010 Oct; 25(10):3241-9. PubMed ID: 20308040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical approaches to management of hyperphosphatemia: can we improve the current situation?
    Kuhlmann MK
    Blood Purif; 2007; 25(1):120-4. PubMed ID: 17170549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hyperphosphatemia.
    Kuhlmann MK
    Hemodial Int; 2006 Oct; 10(4):338-45. PubMed ID: 17014508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study.
    Leung S; McCormick B; Wagner J; Biyani M; Lavoie S; Imtiaz R; Zimmerman D
    BMC Nephrol; 2015 Dec; 16():205. PubMed ID: 26645271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
    Brauer A; Waheed S; Singh T; Maursetter L
    J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to assess the efficacy of phosphate binders.
    Caravaca F; Caravaca-Fontán F; Azevedo L; Luna E
    Nefrologia; 2017; 37(3):311-319. PubMed ID: 28648206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperphosphatemia in dialysis: which binder?].
    Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
    Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies.
    Gutiérrez OM; Wolf M
    Semin Dial; 2010; 23(4):401-6. PubMed ID: 20557490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
    Sherman RA
    Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phosphate binders : What are the recent evidences ?].
    Bouajila IA; Martin PY; De Seigneux S
    Rev Med Suisse; 2017 Feb; 13(551):468-472. PubMed ID: 28714648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.